Clinical Trial Update: Zanzalintinib in Men With Aggressive Variant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Zanzalintinib for aggressive variant prostate cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Variant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Deepak Kilari | Conditions: Aggressive Variant Prostate Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING